Peregrine资本管理公司投资62M美元投资眼科治疗公司Ocular Therapeutix。 Peregrine Capital Management invested $6.2M in Ocular Therapeutix, an eye therapy company.

Peregrine资本管理有限责任公司投资620万美元投资Oclas-Therapeutix Inc.,这是一家以眼科疗法为重点的生物制药公司,购买了847 468股股票。 Peregrine Capital Management LLC invested $6.2 million in Ocular Therapeutix Inc., a biopharmaceutical company focused on eye therapies, buying 847,468 shares. 与此同时,圆形安格尔顾问有限责任公司将其持有量减少了1.3%。 Meanwhile, RoundAngle Advisors LLC reduced its holdings by 1.3%. oclas Therapeutix市场销售DEXTENZA的眼疾药品,市场上限为148亿美元,“Buy”共识评级为17.33美元,目标价格为17.33美元。 Ocular Therapeutix, which markets DEXTENZA for eye conditions, has a market cap of $1.48 billion and a "Buy" consensus rating with a target price of $17.33.